LLY V. NVO: Weighing Who's Winning the GLP-1 Industry

Why It Matters

Efficacy‑driven competition and falling prices are set to expand the GLP‑1 market, reshaping revenue prospects and credit outlooks for Novo Nordisk and Eli Lilly.

Key Takeaways

• Novo's higher‑dose Wegovy priced $399 cash, undercuts Lilly's Zepbound.
• Tirzepatide (Zepbound) remains market leader due to superior efficacy.
• Lilly's pipeline, especially Retatrutide, could surpass Zepbound effectiveness.
• Prices falling; cash‑pay patients likely boost overall GLP‑1 demand.
• Injectables stay dominant, pills serve niche and expand market reach.

Summary

The video examines the intensifying GLP‑1 battle between Novo Nordisk and Eli Lilly, highlighted by Novo’s launch of a higher‑dose Wegovy at $399 cash price, which undercuts Lilly’s Zepbound pricing. It outlines the product landscape—semaglutide versus tirzepatide—and the strategic moves each company is making, including Novo’s new pill formulation slated for 2026.

Analyst Scott from S&P Global Ratings stresses that efficacy remains the primary market driver, positioning tirzepatide (Zepbound/Mounjaro) as the current leader. While Novo’s price cuts may attract price‑sensitive, cash‑pay patients, Lilly’s pipeline—especially the late‑stage Retatrutide—could deliver superior weight‑loss outcomes, potentially reshaping the hierarchy.

Key quotes include Scott’s view that “Zepbound is the most effective product” and his observation that “injectables will remain the main revenue source, with pills filling a niche.” He also notes emerging competitors such as Amgen, Pfizer and Roche, though none yet match Zepbound’s efficacy.

The discussion implies expanding demand as prices fall and more manufacturers enter the space, boosting volume and pressuring credit metrics. S&P maintains a positive outlook for Lilly, citing improving balance sheets, while assigning Novo a stable rating, signaling investors should watch efficacy breakthroughs and pricing dynamics closely.

Original Description

Scott Zari returns to the Watch List and offers the latest updates around the GLP-1 trade and the two companies leading it: Eli Lilly (LLY) and Novo Nordisk (NVO). He sees weight loss drug efficacy being the main decider of who will take the crown. Right now, Scott sees Eli Lilly taking the charge. He sees volume increasing and prices coming down as competition increases.

Segment originally aired Tuesday, April 7, 2026.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

Follow us on X – https://twitter.com/schwabnetwork

Follow us on Facebook – https://www.facebook.com/schwabnetwork

Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/

About Schwab Network - https://schwabnetwork.com/about

#elililly #novonordisk #glp1 #economy #finance #investing #marketnews #stock #stockmarket #trading #live #schwabnetwork #lly #nvo #weightloss #healthcare #wegovy #zepbound #mounjaro #ozempic #chart